Replies to post #123208 on Biotech Values

[genisi]

At the moment, lacking full data from CARE-MS1 trial and awaiting CARE-MS2 trial results, Lemtrada potential place in the MS arena looks at a distant behind Tysabri, Gilenya, and BG12.